We are live on ! Find out more
BIOR

Biora Therapeutics, Inc. Common Stock
BIOR

Delisted

BIOR was delisted on the 10th of December, 2024.

Back to rankings

0 hedge funds and large institutions have $0 invested in Biora Therapeutics, Inc. Common Stock in 2024 Q4 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 19 closing their positions.

New
Increased
Maintained
Reduced
Closed

33.5% less ownership

Funds ownership: 33.5% → 0% (-34%)

100% less funds holding

Funds holding: 20 → 0 (-20)

100% less funds holding in top 10

Funds holding in top 10: 1 → 0 (-1)

100% less capital invested

Capital invested by funds: $6.13M → $0 (-$6.13M)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 19

Holders
–
Holders Change
-20
Holders Change %
-100%
% of All Funds
–
Holding in Top 10
–
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
19
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
-$350K
2
Geode Capital Management
Geode Capital Management
Massachusetts
-$78.4K
3
Morgan Stanley
Morgan Stanley
New York
-$72.7K
4
Northern Trust
Northern Trust
Illinois
-$34.4K
5
BlackRock
BlackRock
New York
-$30.9K

BIOR Hedge Fund Activity: Q4 2024 in Review

0 of the 7,607 institutional investors tracked by Wall St. Rank reported a position in Biora Therapeutics, Inc. Common Stock (BIOR) for Q4 2024, worth a combined $0 — down 100% from $6.13M a quarter earlier.

Sellers outnumbered buyers: 19 funds closed out of BIOR and 0 opened new positions — a net loss of 19 holders — while 0 trimmed existing stakes and 0 added.

The largest seller was Vanguard Group, exiting entirely with an estimated $350K sold.

  • 0 institutional investors held Biora Therapeutics, Inc. Common Stock (BIOR) as of Q4 2024, down from 20 in Q3 2024.
  • Funds reported $0 of Biora Therapeutics, Inc. Common Stock stock for Q4 2024, down 100% quarter-over-quarter.
  • 0 funds opened new Biora Therapeutics, Inc. Common Stock positions in Q4 2024 and 19 closed out, a net change of -19 holders.
  • The largest Biora Therapeutics, Inc. Common Stock seller in Q4 2024 was Vanguard Group, an estimated $350K sold.

Based on aggregated 13F filings for Q4 2024.